Quantum Cyber N.V.
For the period ended Jun 30, 2026. Filed Aug 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 14, 2026
QUCY$0.71+2.4%Stored close · as of Nov 6, 2026
What changed in Management’s Discussion and Analysis?
Read the current filingPrevious report: 10-Q
Period ended 2026-03-31; filed 2026-05-15.
0001213900-26-057738
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of OperationsCurrent report: 10-Q
Period ended 2026-06-30; filed 2026-08-14.
0001213900-26-089465
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of OperationsThe baseline is this issuer’s latest earlier reporting period of the same form that was filed before the current report. A previous 10-Q is a different quarter, not a year-over-year comparison. Amendments are excluded.
Compared 68 previous paragraphs and 78 current paragraphs.
27 unchanged; 21 reworded; 28 added; 19 removed; 1 previous and 2 current paragraphs rearranged.
Tables are not compared: 5 previous and 6 current tables excluded. Dates, whitespace, punctuation and numbering changes are ignored; changes to financial figures remain significant.
A changed paragraph is not evidence that risk increased or decreased. An unchanged paragraph does not establish that risk stayed the same.
Added paragraphs (28)
Current report
We are a technology company focused on developing intelligent, scalable platforms that integrate artificial intelligence (“AI”) and quantum computing to power next-generation control systems for unmanned vehicles, aerial vehicles and underwater vehicles, such as drones, self-driving cars and robotic fleets.
Current report
Our platforms are designed to address the fundamental limitations of classical computing approaches to autonomous vehicle control, specifically the inability to solve high-dimensional, multi-objective optimization problems in real time. By pairing AI-driven adaptive perception and decision-making with quantum computing’s capacity to explore vast solution spaces simultaneously, we believe that our systems enable capabilities that are not achievable through conventional approaches alone. We anticipate investing in research and development to power ultimate commercialization of our drone technology.
Current report
Our core mission is to accelerate the convergence of AI and quantum technologies to deliver safer, more capable, and more efficient autonomous systems for defense, commercial logistics, disaster response, and critical infrastructure operations. We believe this convergence represents a significant technological frontier of the coming decade.
Current report
On February 13, 2026, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Mr. David Lazar that provides for the sale in a private placement of 1,000,000 each of Series A Preferred Shares, Series B Preferred Shares, Series C Preferred Shares, Series D Preferred Shares and Series E Preferred Shares in two closings, with the second closing completed on April 22, 2026.
Current report
Recent Developments
Current report
Name and Ticker Symbol Change
Current report
Business Strategy Expansion
Current report
The Company intends to expand its focus to developing intelligent, scalable platforms that integrate artificial intelligence (“AI”) and quantum computing to power next-generation control systems for unmanned vehicles, aerial vehicles and underwater vehicles, such as drones, self-driving cars and robotic fleets. The Company’s aims to accelerate the convergence of AI and quantum technologies to deliver safer, more capable, and more efficient autonomous systems for defense, commercial logistics, disaster response, and critical infrastructure operations.
Current report
Revenue
Current report
The Company did not report any revenues for the three months ended June 30, 2026 and the three months ended June 30, 2025.
Current report
Research and development expenses for the three months ended June 30, 2026 were $4,553,021 compared to $101,278 for the three months ended June 30, 2025, an increase of $4,451,743. This increase was the result of $4,258,449 recorded as in-process R&D related to the acquisition of technology for quantum antenna from Project LightShift in June 2026.
Current report
Sales and marketing expenses for the three months ended June 30, 2026, were $1,458,470 compared to $857,847 for the three months ended June 30, 2025, an increase of $600,623. This increase was related to an increase in our marketing, advertising and brand awareness expenses in support of the launch of our quantum drones business.
Current report
Comparison of the Six Months Ended June 30, 2026 and 2025
Current report
Revenue
Current report
The Company did not report any revenues for the six months ended June 30, 2026 and the six months ended June 30, 2025.
Current report
Research and development expenses for the six months ended June 30, 2026 were $4,579,321 compared to $190,026 for the six months ended June 30, 2025, an increase of $4,389,295. This increase was the result of $4,258,449 recorded as in-process R&D related to the acquisition of technology for quantum antenna from Project LightShift in June 2026.
Current report
General and administrative expenses for the six months ended June 30, 2026 were $6,032,282 compared to $2,167,152 for the six months ended June 30, 2025, an increase of $3,865,130. The increased expenses were primarily the result of stock based compensation of $1.6 million and compensation charges of $2.0 million, both related to the recruitment of the management team and staffing for our Quantum Drones business.
Current report
Comparison of the Six Months Ended June 30, 2026 and 2025
Current report
Total revenue for the six months ended June 30, 2026 was $184,670 as compared to $286,717 for the six months ended June 30, 2025, a decrease of $102,047. This decrease was attributable to our decision to exit our colorectal cancer screening business in February 2026.
Current report
Cost of revenue for the six months ended June 30, 2026 was $63,951 as compared to $97,128 for the six months ended June 30, 2025, a decrease of $33,177. This decrease was attributable to our decision to exit our colorectal cancer screening business in February 2026. As a result, gross profit decreased by $68,870.
Current report
Other expense, net for the six months ended June 30, 2026 was $152,249 compared to $154,318 for the six months ended June 30, 2025, resulting in decreased other expense (net) of $2,069. This decreased other expense was primarily the result of the gain on sale of the NextGen colorectal cancer assets, net of contractual payments and a $683,433 realization of the foreign currency translation adjustment resulting from the wind up of our German subsidiary.
Current report
Lazar Transactions
Current report
On February 13, 2026, we entered into a Purchase Agreement with David E. Lazar that provides for the sale in a private placement of:
Current report
● (a) 1,000,000 of our series A preferred shares, with a nominal value of €0.01 per share (the “Series A Preferred Shares”), convertible into an aggregate of up to 9 million of our ordinary shares, with a nominal value of €0.01 per share (the “Ordinary Shares”), (b) 1,000,000 of our series B preferred shares, with a nominal value of €0.01 per share (the “Series B Preferred Shares”), convertible into an aggregate of up to 9 million Ordinary Shares and (c) 1,000,000 of our series C preferred shares, with a nominal value of €0.01 per share (the “Series C Preferred Shares” and together with the Series A Preferred Shares and the Series B Preferred Shares, the “First Closing Shares”), convertible, subject to shareholder approval, into an aggregate of up to 9 million Ordinary Shares in exchange for $3 million; and
Current report
● (a) 1,000,000 of our series D preferred shares, with a nominal value of €0.01 per share (the “Series D Preferred Shares”), convertible into an aggregate of up to 225 million Ordinary Shares and (b) 1,000,000 of our series E preferred shares, with a nominal value of €0.01 per share (the “Series E Preferred Shares”, together with the Series D Preferred Shares, the “Second Closing Shares”), convertible, subject to shareholder approval, into an aggregate of up to 225 million Ordinary Shares in exchange for an additional $3 million (collectively, the “Investment”).
Current report
Simultaneous to entering into the Purchase Agreement on February 13, 2026, Mr. Lazar purchased the First Closing Shares at a price of $1.00 per share for aggregate gross proceeds of $3 million (the “First Closing”). The Purchase Agreement provided that Mr. Lazar will purchase and acquire the Second Closing Shares at a price of $1.50 per share for aggregate gross proceeds of $3 million (the “Second Closing”), subject to the satisfaction of certain conditions to closing as provided in the Purchase Agreement. In March 2026, Mr. Lazar prepaid the $3 million for the Second Closing, with the Second Closing consummating on April 22, 2026, following the receipt of requisite shareholder approval. Pursuant to the Purchase Agreement, the net proceeds of the Investment will be used for our operations, including for general corporate and working capital purposes, for expenses related to the Investment and to satisfy certain agreed upon obligations.
Current report
For the six months ended June 30, 2026, cash flows used in operating activities was $5,828,696 compared to $2,277,445 used during the six months ended June 30, 2025. The increase in cash flows used in operating activities of $3,551,251 was primarily the result of increased losses resulting from the investment in operating expenses and working capital to fund the ramp-up of our Quantum Drones business.
Current report
During the six months ended June 30, 2026, generated net cash flow of $899,342 from investing activities compared to $248,042 used during the six months ended June 30, 2025. The improvement in cash flows from investing activities was the result of the sale of our NextGen colorectal cancer screening assets in April 2026.
Removed paragraphs (19)
Previous report
In February 2026, the Board made the decision to close the Company’s colorectal cancer line of business to focus on the pancreatic screening line of business. As a result of that decision, the Board marketed for sale the two groups of assets related to the ColoAlert and NextGen product lines, including the intellectual property for each. The decision also resulted in the termination of all employees in the Company’s subsidiary in Germany, with substantially all termination dates between February and May 2026.
Previous report
Business Highlights, Known Trends, Events, and Uncertainties
Previous report
During the three months ended March 31, 2026, the Company continued to advance its diagnostic portfolio, focused on its pancreatic screening product line under development, including being accepted to present the clinical results for our feasibility studies at American Association for Cancer Research (AACR) 2026 Annual Meeting and the Digestive Disease Week (DDW) 2026. The Company also made the decision to exit its colorectal cancer screening business to focus on the pancreatic screening line of business. As a result of that decision the Board marketed for sale the two groups of assets related to the ColoAlert and NextGen product lines, which were primarily the two lines intellectual property. The decision also resulted in the termination of all employees in the Company’s subsidiary in Germany, with termination dates between February and May 2026. As a result of the closing of subsidiary and proposed sales of intellectual property, the Company has recorded an impairment loss on the value of the intellectual property of $2,640,280 in 2025.
Previous report
Total revenue for the three months ended March 31, 2026 was $170,105 as compared to $152,405 for the three months ended March 31, 2025, an increase of 12%. This increase was attributable to increased sales of ColoAlert to lab partners including last time buys.
Previous report
Cost of revenue for the three months ended March 31, 2026 was $63,951 as compared to $46,745 for the three months ended March 31, 2025, an increase of 37%. This increase was attributable to increased sales of ColoAlert to lab partners including last time buys. As a result, gross profit increased by 1%, while gross margins decreased from 69% to 62% due to a higher level of sales coming from a last time buy with a customer having lower contracted sales price.
Previous report
Research and Development Expenses
Previous report
Sales and Marketing Expenses
Previous report
General and Administrative Expenses
Previous report
Other Income (Expense)
Previous report
Total Revenue
Previous report
The Company is currently developing a product for pancreatic cancer screening. During 2026 the Company’s intention is to focus its efforts on continued development and marketing efforts related to its path to commercialization in the U.S.
Previous report
Research and Development Expenses
Previous report
Research and development expenses for the three months ended March 31, 2026 were $59,300 compared to $88,748 for the three months ended March 31, 2025, a decrease of $29,448. This decrease was the result of increased costs in 2025 related to a feasibility study.
Previous report
Sales and Marketing Expenses
Previous report
General and Administrative Expenses
Previous report
Other Income (Expense)
Previous report
For the three months ended March 31, 2026, cash flows used in operating activities was $2,707,993 compared to $3,942,073 used during the three months ended March 31, 2025. The improvement in cash flows used in operating activities of $1,234,080 was primarily the result of our decision to exit our colorectal cancer business and wind down operations in our German subsidiary.
Previous report
During the three months ended March 31, 2026, we used $650,658 in investing activities compared to $198,042 used during the three months ended March 31, 2025. The increase in cash flows used in investing activities of $452,616 was the primarily the result payments related to the acquisition of our intellectual property related to blood based testing for pancreatic cancer.
Previous report
These conditions are indicators that impact the Company’s ability to continue as a going concern for a period of one year from the issuance of these financial statements. If the Company is unable to obtain funding, the Company could be forced to further delay, reduce or eliminate its research and development, regulatory, and commercial efforts which could adversely affect its future business prospects and its ability to continue as a going concern.
Reworded paragraphs (21)
Previous wording
You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and the related notes. Some of the information contained in this discussion and analysis or set forth elsewhere, including information with respect to its plans and strategy for our business and related financing, includes forward-looking statements that involve risks, uncertainties and assumptions. You may read the “Forward-Looking Statements” section in this annual report and the sections entitled “Risk Factors” in other documents that we have filed with the U.S. Securities and Exchange Commission for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.
Current wording
You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and the related notes. Some of the information contained in this discussion and analysis or set forth elsewhere, including information with respect to its plans and strategy for our business and related financing, includes forward-looking statements that involve risks, uncertainties and assumptions. You may read the “Forward-Looking Statements” section in this quarterly report and the sections entitled “Risk Factors” in other documents that we have filed with the U.S. Securities and Exchange Commission for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.
Previous wording
The following discussion refers to our financial results for the three months ended March 31, 2026 and 2025. For purposes of this following discussion the terms “we”, ‘our” or “us” or “the Company” and similar references refers to Quantum Cyber N.V. (f/k/a Mainz Biomed N.V.) and its affiliates.
Current wording
The following discussion refers to our financial results for the three and six months ended June 30, 2026 and 2025. For purposes of this following discussion the terms “we”, ’our” or “us” or “the Company” and similar references refers to Quantum Cyber N.V. (f/k/a Mainz Biomed N.V.) and its affiliates.
Previous wording
Historically we have focused on developing and selling in-vitro diagnostic (“IVD”) tests for the early detection of cancer. During 2025 and early 2026, our legacy ColoAlert product was marketed and sold in European markets. Since 2020, we have been developing both a blood and stool test for the early detection of pancreatic cancer. From 2022 to February 2026, we were developing our next generation colorectal cancer screening product, with the intention to launch these products in the future in the United States and in Europe.
Current wording
Historically we had focused on developing and selling in-vitro diagnostic tests for the early detection of cancer. During 2025 and early 2026, our legacy ColoAlert product was marketed and sold in European markets. Since 2020, we have also been developing both a blood and stool test for the early detection of pancreatic cancer. From 2022 to February 2026, we were developing our next generation colorectal cancer screening product, with the intention to launch these products in the future in the United States and in Europe.
Previous wording
In February 2026, the Board made the decision to close our colorectal cancer line of business to focus on the pancreatic screening line of business. As a result of that decision the Board marketed for sale the two groups of assets related to the ColoAlert and NextGen product lines, which were primarily the intellectual property and related assets. The sales of these product lines and intellectual property were completed in two independent transactions in March and April 2026. In conjunction with this decision also resulted in the termination of all employees of our subsidiary in Germany, with termination dates between February and May 2026.
Current wording
In February 2026, the Company’s Board of Directors made the decision to close our colorectal cancer line of business to focus on the pancreatic screening line of business.
Previous wording
General and administrative expenses for the three months ended March 31, 2026 were $2,121,840 compared to $1,496,202 for the three months ended March 31, 2025, an increase of $625,638. The increased expenses were primarily the result of stock based compensation and compensation charges.
Current wording
General and administrative expenses for the three months ended June 30, 2026 were $3,877,442 compared to $670,950 for the three months ended June 30, 2025, an increase of $3,206,492. The increased expenses were primarily the result of stock based compensation of $1.5 million and compensation charges of $1.4 million, both related to the recruitment of the management team and staffing for our quantum drones business.
Previous wording
Other expense, net for the three months ended March 31, 2026 was $22,552 compared to $21,932 for the three months ended March 31, 2025, resulting in increased other expenses (net) of $620. This increase was primarily the result of decreased interest expense offset by increased other expense for the three months ended March 31, 2026 compared to the same period in 2025.
Current wording
Other expense, net for the three months ended June 30, 2026 was $183,387 compared to $51,910 for the three months ended June 30, 2025, resulting in increased other expenses of $131,477. This increase was primarily the result of decreased interest expense offset by increased other expense for the three months ended June 30, 2026 compared to the same period in 2025.
Previous wording
Sales and marketing expenses for the three months ended March 31, 2026, were $281,903 compared to $1,160,575 for the three months ended March 31, 2025, a decrease of $878,672. This decrease was related to a decrease in our marketing and advertising expenses in line with our decision to exit our colorectal cancer business.
Current wording
Sales and marketing expenses for the six months ended June 30, 2026, were $1,740,373 compared to $2,018,422 for the six months ended June 30, 2025, a decrease of $278,049. This decrease was related to a decrease in our marketing and advertising expenses in line with our decision to exit our colorectal cancer business.
Previous wording
Other expense, net for the three months ended March 31, 2026 was $29,074 compared to $61,259 for the three months ended March 31, 2025, resulting in decreased other expenses (net) of $32,185. This decrease was primarily the result of decreased interest expense for the three months ended March 31, 2026 compared to the same period in 2025.
Current wording
Other expense, net for the six months ended June 30, 2026 was $205,939 compared to $73,842 for the six months ended June 30, 2025, resulting in increased other expenses (net) of $132,097. This increase was primarily the result of decreased interest expense offset by increased other expense for the six months ended June 30, 2026 compared to the same period in 2025.
Previous wording
Research and development expenses for the three months ended March 31, 2026 were $1,152,082 compared to $1,624,797 for the three months ended March 31, 2025, a decrease of $420,278. This decrease was driven by a reduction of costs of resulting from wind down of the eAArly Detect 2 clinical study.
Current wording
Research and development expenses for the six months ended June 30, 2026 were $1,704,714 compared to $2,802,258 for the six months ended June 30, 2025, a decrease of $1,097,544. This decrease was driven by a reduction of costs resulting from the wind down of the eAArly Detect 2 clinical study.
Previous wording
Sales and marketing expenses for the three months ended March 31, 2026, were $393,275 compared to $176,400 for the three months ended March 31, 2025, an increase of $216,875. This increase was related to severance related to the termination of our colorectal cancer screening sales and marketing team.
Current wording
Sales and marketing expenses for the six months ended June 30, 2026, were $405,791 compared to $330,583 for the six months ended June 30, 2025, an increase of $75,208. This increase was related to severance related to the termination of our colorectal cancer screening sales and marketing team.
Previous wording
General and administrative expenses for the three months ended March 31, 2026 were $538,393 compared to $478,638 for the three months ended March 31, 2025, an increase of $59,755. The increased expenses were primarily the result of a severance payments for administration and accounting personnel.
Current wording
General and administrative expenses for the six months ended June 30, 2026 were $1,398,512 compared to $872,908 for the six months ended June 30, 2025, an increase of $525,604. The increased expenses were primarily the result of severance payments for administration and accounting personnel.
Previous wording
Our principal liquidity requirements are for working capital and operating losses. We fund our liquidity requirements primarily through cash on hand, cash flows from operations and, debt and equity financing. As of March 31, 2026, we had $4,752,966 of cash and cash equivalents, compared to $889,091 as of December 31, 2025.
Current wording
Our principal liquidity requirements are for working capital and funding operations. We fund our liquidity requirements primarily through cash on hand, and, debt and equity financing. As of June 30, 2026, we had $13,454,652 of cash and cash equivalents, compared to $889,091 as of December 31, 2025.
Previous wording
We do not disclose cash flow from discontinued operation separately in the statement of cash flows and disclose cash flow from discontinued operation in the footnote. The following table summarizes our cash flows from operating, investing and financing activities, for the three months ended March 31, 2026 and 2025:
Current wording
We do not disclose cash flow from discontinued operations separately in the statement of cash flows and disclose cash flow from discontinued operations in the footnotes to the financial statements. The following table summarizes our cash flows from continuing operations, for the six months ended June 30, 2026 and 2025:
Previous wording
During the three months ended March 31, 2026, we used $350,658 in investing activities compared to $198,042 used during the three months ended March 31, 2025. The increase in cash flows used in investing activities was the result of increased payments related to the ColoAlert acquisition debt.
Current wording
During the six months ended June 30, 2026, cash flows used in investing activities was $636,799 in investing activities compared to $200,000 used during the six months ended June 30, 2025. The increase in cash flows from investing activities of $436,799 was primarily the result of increased capital expenditures to fund the ramp up of our Quantum Drones business.
Previous wording
During the three months ended March 31, 2026, we had cash flow provided by financing activities of $7,267,225 compared to cash flow used in financing activities of $356,958 for the three months ended March 31, 2025, an increase of $7,624,183. This increase was primarily the result of the Company’s sale of preferred stock for $6 million and $2.1 million from the sale of its ordinary shares pursuant to its Equity Distribution Agreement, reduced by repayments of debt of $821,013.
Current wording
During the six months ended June 30, 2026, we had cash flow provided by financing activities of $19,139,937 compared to cash flow used in financing activities of $1,868,153 for the six months ended June 30, 2025, an increase of $21,008,090. This increase was primarily the result of the Company’s sale of preferred stock for $6 million and $15.2 million from the exercise of warrants.
Previous wording
For the three months ended March 31, 2026, cash flows used in operating activities was $1,842,893 compared to $2,740,972 used during the three months ended March 31, 2025. The improvement in cash flows used in operating activities is attributable to a reduction of costs resulting from wind down of the eAArly Detect 2 clinical study.
Current wording
For the six months ended June 30, 2026, cash flows used in operating activities was $4,068,404 compared to $4,346,784 used during the six months ended June 30, 2025. The improvement in cash flows used in operating activities is attributable to a reduction of costs resulting from the wind down of the eAArly Detect 2 clinical study.
Previous wording
During the three months ended March 31, 2026, we had cash flow provided by financing activities of $2,353,534 compared to cash flow provided by financing activities of $2,806,493 for the three months ended March 31, 2025, a decrease of $452,959. This decrease was primarily the result of the decreased need for intercompany financing to fund operating losses, in line with the Company’s decision to wind down its German subsidiary.
Current wording
During the six months ended June 30, 2026, we had cash flow provided by financing activities of $3,091,143 compared to cash flow provided by financing activities of $4,631,779 for the six months ended June 30, 2025, a decrease of $1,540,636. This decrease was primarily the result of the decreased need for intercompany financing to fund operating losses, in line with the Company’s decision to wind down its German subsidiary.
Previous wording
We had recurring losses, accumulated deficit totaling $110.0 million and negative cash flows used in operating activities of $2.7 million as of and for the three months ended March 31, 2026. We also had $4.5 million of cash on hand on March 31, 2026, and working capital of $3.5 million.
Current wording
We had recurring losses, an accumulated deficit totaling $121.0 million and negative cash flows used in operating activities of $9.9 million as of and for the six months ended June 30, 2026. We also had $13.4 million of cash on hand on June 30, 2026, and working capital of $13.7 million.
Previous wording
Historically, the Company has relied upon funds from its stockholders and loans from third parties. Management may raise additional capital through future public or private offerings of the Company’s stock or through loans from private investors, although there can be no assurance that it will be able to obtain such financing. The Company’s failure to do so could have a material and adverse effect upon its operations and its stockholders.
Current wording
Historically, the Company has relied upon funds from its stockholders and loans from third parties. Management may raise additional capital through future public or private offerings of the Company’s stock or through loans from private investors, although there can be no assurance that it will be able to obtain such financing.
Previous wording
We plan to fund our cash flow and working capital needs through current cash on hand and future debt and/or equity financings which we may obtain through one or more public or private equity offerings, debt financings, government or other third-party funding, strategic alliances or collaboration agreements. During early 2026, the Company completed a $6 million preferred stock offering and has an Equity Distribution Agreement in place which allows the Company to raise additional equity capital.
Current wording
We plan to fund our cash flow and working capital needs through current cash on hand and future debt and/or equity financings which we may obtain through one or more public or private equity offerings, debt financings, government or other third-party funding, strategic alliances or collaboration agreements. During the first half of 2026, the Company completed a $6 million preferred stock offering and received proceeds from the exercise of outstanding stock warrants of $15.2 million.
Previous wording
The Company believes that its currently available cash on hand, together with additional financing described above, may be sufficient to meet its planned expenditures and obligations for at least the one-year period following the issuance of its consolidated financial statements; however, such expectations are subject to significant uncertainty, and substantial doubt remains about the Company’s ability to continue as a going concern.
Current wording
The Company believes that its currently available cash on hand, together with additional financing described above, will be sufficient to meet its planned expenditures and obligations for at least the one-year period following the issuance of its consolidated financial statements.
Rearranged current paragraphs (2)
Current report — wording carried from elsewhere
In April 2026, the Company changed its name, from Mainz Biomed N.V., to Quantum Cyber N.V. In conjunction with the name change, the Company changed its NASDAQ ticker symbol to “QUCY”.
Current report — wording carried from elsewhere
The following table provides certain selected financial information for the periods presented, from our continuing operations:
Rearranged previous paragraphs (1)
Previous report — wording carried elsewhere
Comparison of the Three Months Ended March 31, 2026 and 2025